Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology

JAMA Oncology

Volumn 4, Issue 8, 2018, Pages 1093-1098

  Marquart, John ^a   Chen, Emerson Y ^a   Prasad, Vinay ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; DABRAFENIB; ENASIDENIB; IMATINIB; MIDOSTAURIN; NIVOLUMAB; PEMBROLIZUMAB; TRAMETINIB; TRASTUZUMAB; VEMURAFENIB; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOID LEUKEMIA; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER GENE THERAPY; CANCER INCIDENCE; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; CROSS-SECTIONAL STUDY; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; GENE TARGETING; GENETIC DISORDER; HUMAN; MALIGNANT NEOPLASM; MELANOMA; METASTASIS; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SOLID MALIGNANT NEOPLASM; TREATMENT DURATION; TREATMENT INDICATION; UNITED STATES; GENE EXPRESSION PROFILING; GENETICS; MOLECULARLY TARGETED THERAPY; NEOPLASM; PATHOLOGY; PERSONALIZED MEDICINE; PHARMACOGENETICS; PROGNOSIS;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CROSS-SECTIONAL STUDIES; DRUG APPROVAL; GENE EXPRESSION PROFILING; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHARMACOGENETICS; PRECISION MEDICINE; PROGNOSIS; RETROSPECTIVE STUDIES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85051012462     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2018.1660     Document Type: Article

References (28)

1. Hyman DM, Taylor BS, Baselga J. Implementing genome-driven oncology. Cell. 2017;168(4):584-599.
2. Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol. 2013;31(15):1806-1814.
3. Grossman RL, Heath AP, Ferretti V, et al. Toward a shared vision for cancer genomic data. N Engl J Med. 2016;375(12):1109-1112.
4. ChiaS,LowJ-L,ZhangX,etal.Phenotype-driven precisiononcologyasaguideforclinicaldecisionsone patientatatime.NatCommun.2017;8(1):435.
5. Simon R. Genomic alteration-driven clinical trial designs in oncology. Ann Intern Med. 2016;165(4): 270-278.
6. Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
7. Slamon DJ,Leyland-Jones B,Shak S,etal.Useof chemotherapyplusamonoclonalantibodyagainstHER2 formetastaticbreastcancerthatoverexpressesHER2. NEnglJMed.2001;344(11):783-792.
8. US Food and Drug Administration.Hematology/ Oncology(Cancer)Approvals&SafetyNotifications: ApprovedDrugs2018;https://www.fda.gov/Drugs /InformationOnDrugs/ApprovedDrugs/ucm279174 .htm.AccessedMarch22,2018.
9. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
10. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32(4):605-644. doi:10.1016/j.ccm .2011.1009.1001
11. Morgensztern D, Campo MJ, Dahlberg SE, et al. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 2015;10(1)(suppl 1):S1-S63.
12. Zia MI, Siu LL, Pond GR, Chen EX. Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. J Clin Oncol. 2005;23(28):6982-6991.
13. Rogers E. Diffusion of Innovations. 5th ed. New York, NY: Free Press; 2003.
14. Prasad V. Why the US Centers for Medicare and Medicaid Services (CMS) should have required a randomized trial of Foundation Medicine (F1CDx) before paying for it. Ann Oncol. 2018;29(2):298-300.
15. Massard C, Michiels S, Ferté C, et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 Trial. Cancer Discov. 2017;7(6):586-595.
16. Wheler JJ,Janku F,Naing A,etal.Cancertherapy directedbycomprehensivegenomicprofiling:asingle centerstudy.CancerRes.2016;76(13):3690-3701.
17. Fojo T. Precision oncology: a strategy we were not ready to deploy. Semin Oncol. 2016;43(1):9-12.
18. Prasad V, Fojo T, Brada M. Precision oncology: origins, optimism, and potential. Lancet Oncol. 2016;17(2):e81-e86.
19. Prasad V. Perspective: the precision-oncology illusion. Nature. 2016;537(7619):S63.
20. Tannock IF, Hickman JA. Limits to personalized cancer medicine. N Engl J Med. 2016;375(13):1289-1294.
21. West HJ. No solid evidence, only hollow argument for universal tumor sequencing: show me the data. JAMA Oncol. 2016;2(6):717-718.
22. West HJ. Can we define and reach precise goals for precision medicine in cancer care? J Clin Oncol. 2016;JCO688226.
23. Letai A. Functional precision cancer medicine-moving beyond pure genomics. Nat Med. 2017;23(9):1028-1035.
24. Jaffee EM,Dang CV,Agus DB,etal.Futurecancer research priorities in the USA: a Lancet Oncology Commission.LancetOncol.2017;18(11):e653-e706.
25. Enewold L, Thomas A. Real-world patterns of EGFR testing and treatment with erlotinib for non-small cell lung cancer in the United States. PLoS One. 2016;11(6):e0156728.
26. Abernethy AP,Fung C,Richardson P,etal.BRAF,KIT, andNRAStestingpatternsandresultsinmetastatic melanoma[publishedonlineJune30,2015].JClin Oncol.doi:10.1200/jco.2015.33.15_suppl.e20089
27. Cancer Staging.Treatment&Support2015; https://www.cancer.org/treatment/understanding-your-diagnosis/staging.html.AccessedMarch22,2018.
28. Wagner J, Marquart J, Ruby J, et al. Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study. BMJ. 2018;360:k668.